Next Article in Journal
Gata3 Silencing Is Involved in Neuronal Differentiation and Its Abnormal Expression Impedes Neural Activity in Adult Retinal Neurocytes
Previous Article in Journal
Investigation of the Molecular Details of the Interactions of Selenoglycosides and Human Galectin-3
Previous Article in Special Issue
Spontaneous CD4+ T Cell Activation and Differentiation in Lupus-Prone B6.Nba2 Mice Is IFNAR-Independent
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 23
Issue 5
10.3390/ijms23052505
Review Report
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Type I Interferons in Systemic Lupus Erythematosus: A Journey from Bench to Bedside

Int. J. Mol. Sci. 2022, 23(5), 2505; https://doi.org/10.3390/ijms23052505
by Tao Ming Sim 1, Siying Jane Ong 2, Anselm Mak 1,2 and Sen Hee Tay 1,2,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2022, 23(5), 2505; https://doi.org/10.3390/ijms23052505
Submission received: 30 January 2022 / Revised: 21 February 2022 / Accepted: 21 February 2022 / Published: 24 February 2022
(This article belongs to the Special Issue Interferons in Lupus)

Round 1

Reviewer 1 Report

In this narrative review, the Authors nicely discuss the biologic background regarding the IFN pathways leading to SLE and analyze the results of RCT published up to now with a prticular emphasis about anifrolumab.

The paper is well written, and the most relevant issues related to the therapeutic approach focused on inhibition of IFN pathways in SLE are covered and well discussed.

Although the Authors already mention (see paragraph n. 2) the relationships between anti-RBP antibodies and IFN gene signature, I suggest to add a new reference related to a recently published paper [1] focusing on this topic.

[1] Anti-RNP antibodies are associated with the interferon gene signature but not decreased complement levels in SLE. Erika L Hubbard, David S Pisetsky, Peter E Lipsky (2022-02-03). 10.1136/annrheumdis-2021-221662

 

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

In this manuscript entitled “Type I Interferons in Systemic Lupus Erythematosus: A Journey From Bench to Bedside”, the authors describe the discovery of interferons, their potential contribution of type 1 interferon in SLE (but not limited to type 1 only), and association with clinical features. Finally, the results of clinical trials targeting type 1 IFN in SLE are also well summarized. The manuscript is well-written and deserves publication in its present format.

 

I would only like to recommend the authors to provide the results of anifrolumab treatment in patients with lupus nephritis, which was published recently (Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis (PMID: 35144924)).

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Back to TopTop